Ara
Toplam kayıt 4, listelenen: 1-4
Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
(2015)
Ruxolitinib, a JAK1 and JAK2 inhibitor drug, has recently been approved for the treatment of patients with high- or intermediate-risk myelofibrosis with symptomatic splenomegaly. Ruxolitinib is the first clinically useful ...
Co-Expression Of T(15;17) And T(8;21) In A Case Of Acute Promyelocytic Leukemia: Review Of The Literature
(2013)
Additional chromosomal abnormalities in acute myelogenous leukemia have been identified as one of the most important prognostic factors. Favorable chromosomal changes such as t(8;21), inv(16), and t(15;17) are associated ...
The Prognosis Of Adult Burkitt’S Cell Leukemia In Real-Life Clinical Practice
(2016)
Objective: Many studies reported an improved prognosis in patients with Burkitt’s lymphoma obviating the need of stem cell transplantation. However, prognosis of the advanced disease [i.e. Burkitt’s cell leukemia (BCL)] ...